The Amsterdam-based company’s BlueControl is designed as a rechargeable, wearable device which can be comfortably used on the arms, legs, elbows and knees using adjustable straps. The company won CE Mark approval in the European Union for the device in 2015.
“As a company, we aim to improve people’s health with a broad portfolio of proven therapy solutions to enable patients with chronic conditions to manage their health at home. Philips BlueControl is a clinically proven light therapy device that can be easily integrated into a patient’s daily routine. We are pleased that we can now start marketing this innovative home treatment solution for psoriasis to dermatologists in the U.S., so that they will be able to prescribe Philips BlueControl to their patients,” Philips light & health biz GM David Aubert said in a press release.
Philips said that with the clearance, it will begin to engage with dermatologists and patient support groups in the US with a slated commercial launch in early 2018.
Earlier this month, Philips said it paid an unspecified amount to acquire stealthy CardioProlific and the peripheral thrombectomy catheters it’s developing.